ReShape Lifesciences enters up to $5M equity purchase agreement with investor

Vyome Holdings, Inc

Equity purchase agreement for up to $5M over 36 months; pricing at 93% of prior-day VWAP with a true-up mechanism.
Investor receives 17,300 shares and pre-funded warrant for 21,015 shares as commitment fee; short selling prohibited.
Issuance capped at 19.9% of outstanding shares unless stockholder approval or price exceeds Nasdaq Official Closing Price thresholds.
Proceeds expected for working capital and merger with Vyome Therapeutics; 66% of net proceeds must prepay existing convertible note.
Company filed S-1 to register resale of shares; agreement may be terminated by Company on 5 days' notice.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.